Aggressive Lipid Management for Cardiovascular Prevention英文资料.pdfVIP

MINIREVIEW Aggressive Lipid Management for Cardiovascular Prevention: Evidence from Clinical Trials KAREN E. FRIDAY1 Department Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112 Epidemiologic evidence shows that elevated serum cholesterol, oronary heart disease (CHD) is a major medical and specifically low-density lipoprotein cholesterol (LDL-C), in- economic issue in the United States (1). Overall, creases the risk of coronary heart disease (CHD). Moreover, C12.2 million people have a history of myocardial large-scale intervention trials demonstrate that treatment with HMG-CoA reductase inhibitors (statins), the most effective drug infarction (MI), angina pectoris, or both, and each year 1.1 class for lowering LDL-C, significantly reduces the risk of CHD million people suffer a new or recurrent MI. CHD is the events. Unfortunately, only a moderate percentage of hypercho- leading cause of death, being responsible for more than lesterolemic patients are achieving LDL-C targets specified by the National Cholesterol Education Program (NCEP), in part be- 466,000 deaths annually, or one in five of all deaths in this cause clinicians are not effectively titrating medications as country. Patients who survive the acute stage of an MI have needed to achieve LDL-C goals. Recent evidence suggests that up to 15 times higher risk of illness and death than the more aggressive LDL-C lowering may provide greater clinical general population, depending on their age, sex, and clinical benefit, even in individuals